Please assess the completion status of the following clinical trial:

Trial Title: Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with proven diagnosis of multiple myeloma~* Patients must be enrolled in treatment with novel agents (Bortezomib/Lenalidomide/Ixazomib/Daratumumab)~* Patients must have Creatinine Clearance above 30 mL/min on the Day 1 of trial~* Patients must have given informed consent to participate in trial.~Exclusion Criteria:~* Contraindication to the use of one of the study drug/vaccines (including known hypersensitivity)~* Creatinine Clearance below 30 mL/min on the Day 1 of trial~* Psychiatric disorder or unable to understand or to follow the protocol directions~* Active bacterial, viral, fungal or protozoal infection on the Day 1 of trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Vaccination group (Type: EXPERIMENTAL): Patients receiving novel agents (Bortezomib/Lenalidomide/Ixazomib/Daratumumab) and enrolled in vaccination by pneumococcal conjugate vaccine (PCV13): 3 doses with 1 month interval, and fourth dose planned to be administered 6 months later.
- Standard prophylaxis (Type: ACTIVE_COMPARATOR): Patients receiving novel agents (Bortezomib/Lenalidomide/Ixazomib/Daratumumab) and receiving standard institutional antibacterial prophylaxis by Levofloxacin 500 mg daily during the median four cycles of treatment by novel agents

Based on this trial design, predict the completion outcome and termination type (if applicable).